We're a global pharmaceutical company that has a world-class ... And in the context of Teva and AUSTEDO still growing and then the 3 products I've just mentioned, from a forecasting point of view, ...

Controversial fentanyl lollipops and similar products will no longer be made by drug makers, the U.S. Food and Drug A ...

Drugmaker Cephalon had the FDA's approval to market these drugs, old under brand names like Actiq, as a sweetened lozenge on ...

The long-term safety of TEV-‘749 and incidence of PDSS are also being evaluated in the SOLARIS open-label study (Period 2), with safety data topline readout expected in the first half of 2025.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Barclays analyst Balaji Prasad assigned a Buy rating to Elanco Animal Health (ELAN – Research Report) today and set a price target of ...

Barclays analyst Balaji Prasad maintained a Buy rating on Organon (OGN – Research Report) today and set a price target of $26.00. The ...

Despite FDA restrictions, drugmakers, including Cephalon and later its parent company Teva pharmaceuticals, faced lawsuits for downplaying the drug's addiction risks and promoting the medication to ...

Corcept is a profitable biotech company with significant potential for growth, focusing on treating Cushing's Syndrome and ...